Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
23 hedge funds and large institutions have $7.87M invested in Landos Biopharma, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 12 closing their positions.
26% less funds holding
Funds holding: 31 → 23 (-8)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
44% less capital invested
Capital invested by funds: $14M → $7.87M (-$6.17M)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$20.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.06K |
| 3 |
Jane Street
New York
|
+$5.68K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.62K |
| 5 |
SGCA
Steel Grove Capital Advisors
Memphis,
Tennessee
|
+$3.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$2.58M |
| 2 |
OMC
OUP Management Company
Bala Cynwyd,
Pennsylvania
|
-$804K |
| 3 |
BlackRock
New York
|
-$104K |
| 4 |
AI
ArchPoint Investors
Coral Gables,
Florida
|
-$83K |
| 5 |
Renaissance Technologies
New York
|
-$51K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| – | -$11K | -1,648 | Closed |
|
27
Balyasny Asset Management
Chicago,
Illinois
| – | -$10K | -1,569 | Closed |
|
28
Man Group
London,
United Kingdom
| – | -$9K | -1,439 | Closed |
|
29
Goldman Sachs
New York
| – | -$9K | -1,309 | Closed |
|
|
SWP
30
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$7K | -1,000 | Closed |
|
31
JP Morgan Chase
New York
| – | -$624 | -163 | -73% |
|
32
BNP Paribas Financial Markets
Paris,
France
| – | -$729 | -112 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$119 | -31 | -45% |
|
LABP Hedge Fund Activity: Q4 2022 in Review
23 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q4 2022, worth a combined $7.87M — down 44% from $14M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LABP and 4 opened new positions — a net loss of 8 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $20.1K. The largest seller was RTW Investments, exiting entirely with an estimated $2.58M sold.
- 23 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q4 2022, down from 31 in Q3 2022.
- Funds reported $7.87M of Landos Biopharma, Inc. Common Stock stock for Q4 2022, down 44% quarter-over-quarter.
- 4 funds opened new Landos Biopharma, Inc. Common Stock positions in Q4 2022 and 12 closed out, a net change of -8 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q4 2022 was HRT Financial, an estimated $20.1K added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q4 2022 was RTW Investments, an estimated $2.58M sold.
Based on aggregated 13F filings for Q4 2022.